<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="987">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05148299</url>
  </required_header>
  <id_info>
    <org_study_id>Sobi.PEGCET-201</org_study_id>
    <nct_id>NCT05148299</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of Pegcetacoplan in Patients With TA-TMA After Hematopoietic Stem Cell Transplantation (HSCT)</brief_title>
  <official_title>An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Pegcetacoplan in Patients With Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Swedish Orphan Biovitrum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess PK, Pharmacodynamics (PD) and safety of pegcetacoplan&#xD;
      in patients with TA-TMA after HSCT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label, single arm, multicenter</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pegcetacoplan PK parameter AUC0-tau</measure>
    <time_frame>Week 24</time_frame>
    <description>Area under the concentration-time curve over the dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pegcetacoplan PK parameter Cmax</measure>
    <time_frame>Week 24</time_frame>
    <description>Maximum observed serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pegcetacoplan PK parameter Tmax</measure>
    <time_frame>Week 24</time_frame>
    <description>Time of maximum measured serum concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pegcetacoplan PK parameter Ctrough</measure>
    <time_frame>Week 24</time_frame>
    <description>Observed serum concentration predose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute levels, change from baseline, and percent change in sC5b-9</measure>
    <time_frame>Week 24</time_frame>
    <description>Absolute levels, change from baseline, and percent change from baseline to Week 24 in biomarker of complement activation sC5b-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants reaching clinical response at week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>A participant will be declared as reaching a clinical response upon improvement in laboratory markers of TMA and resolution of TMA clinical symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Day 100 from diagnosis</time_frame>
    <description>Survival</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with treatment-related adverse events.</measure>
    <time_frame>From treatment start to end of study, an average of 6 months</time_frame>
    <description>Occurrence and severity of treatment-emergent adverse events.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with clinically significant changes in vital signs.</measure>
    <time_frame>Week 24</time_frame>
    <description>Occurrence of clinically significant changes in vital signs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with clinically significant changes in abnormal electrocardiogram findings.</measure>
    <time_frame>Week 24</time_frame>
    <description>Occurrence of clinically significant abnormal electrocardiogram findings.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Transplant-Associated Thrombotic Microangiopathy</condition>
  <arm_group>
    <arm_group_label>Pegcetacoplan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegcetacoplan</intervention_name>
    <description>20-cc glass vials-1080 mg</description>
    <arm_group_label>Pegcetacoplan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients aged ≥ 18 years at the time of informed consent form (ICF)&#xD;
             signature.&#xD;
&#xD;
          2. Received allogeneic HSCT.&#xD;
&#xD;
          3. Diagnosis of TA-TMA established by histologic evidence of microangiopathy in any&#xD;
             biopsied organ OR, as per laboratory markers indicating TMA.&#xD;
&#xD;
          4. Have a diagnosis of TA-TMA that persists despite initial management of any triggering&#xD;
             condition.&#xD;
&#xD;
          5. Have at least 1 sign/symptom of organ dysfunction.&#xD;
&#xD;
          6. Women of childbearing potential, defined as any women who have experienced menarche&#xD;
             and who are NOT permanently sterile or postmenopausal, must have a negative serum&#xD;
             pregnancy test at screening and agree to use protocol-defined methods of contraception&#xD;
             for the duration of the study and 8 weeks after their last IMP dose.&#xD;
&#xD;
             Note: Postmenopausal is defined as having had 12 consecutive months with no menses&#xD;
             without an alternative medical cause.&#xD;
&#xD;
          7. Men must agree to the following for the duration of the study and 8 weeks after their&#xD;
             last dose of IMP:&#xD;
&#xD;
               1. Avoid fathering a child.&#xD;
&#xD;
               2. Use protocol-defined methods of contraception.&#xD;
&#xD;
               3. Refrain from donating sperm.&#xD;
&#xD;
          8. Patient and/or legally authorized representative must be capable of giving signed&#xD;
             informed consent, which includes compliance with the requirements and restrictions&#xD;
             listed in the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive direct Coombs test.&#xD;
&#xD;
          2. Known familial or acquired ADAMTS13 deficiency.&#xD;
&#xD;
          3. Known Shiga toxin-related hemolytic uremic syndrome.&#xD;
&#xD;
          4. Known bone marrow or graft failure.&#xD;
&#xD;
          5. Diagnosis of disseminated intravascular coagulation.&#xD;
&#xD;
          6. Diagnosis of veno-occlusive disease (VOD).&#xD;
&#xD;
          7. Active GI bleeding (hematemesis or hematochezia) at baseline.&#xD;
&#xD;
          8. Body weight &lt; 30 kg and &gt; 100 kg.&#xD;
&#xD;
          9. Uncontrolled systemic bacterial or fungal infection, presence or suspicion of sepsis.&#xD;
&#xD;
         10. Previously or currently treated with a complement inhibitor (approved or&#xD;
             investigational).&#xD;
&#xD;
         11. Pregnancy or breastfeeding.&#xD;
&#xD;
         12. Positive human immunodeficiency virus antibody at screening or documented in pre-HSCT&#xD;
             medical record.&#xD;
&#xD;
         13. Hepatitis C virus detectable by polymerase chain reaction at screening or documented&#xD;
             in pre-HSCT medical record.&#xD;
&#xD;
         14. Chronic inactive hepatitis B virus with viral loads &gt; 1000 IU/mL (&gt; 5000 copies/mL) at&#xD;
             screening or documented in pre-HSCT medical record. Eligible patients who are chronic&#xD;
             active carriers (≤ 1000 IU/mL) must receive prophylactic antiviral treatment (e.g.,&#xD;
             entecavir, tenofovir, lamivudine) according to local country guidelines.&#xD;
&#xD;
         15. Inability to cooperate with study procedures or any condition that, in the opinion of&#xD;
             the investigator, could increase the patient's risk by participating in the study or&#xD;
             confound the outcome of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Mappa, MD</last_name>
    <phone>+39 342 7706061</phone>
    <email>silvia.mappa@sobi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Athens</city>
        <zip>10676</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Thessaloníki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Avellino</city>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 24, 2021</last_update_submitted>
  <last_update_submitted_qc>November 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TA-TMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

